Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,164 matching trials from the live ClinicalTrials.gov search.
Conditions
Influenza, Human
Interventions
bioCSL Trivalent Influenza Virus Vaccine (CSL TIV), Comparator Quadrivalent Influenza Virus Vaccine
Biological
Lead sponsor
Seqirus
Industry
Eligibility
5 Years to 8 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
11
States / cities
Los Angeles, California • Boise, Idaho • St Louis, Missouri + 8 more
Conditions
Influenza, Fever
Interventions
Mammalian cell based flu vaccine, Egg based flu vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
4 Years to 17 Years
Enrollment
2,055 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
18
States / cities
Mobile, Alabama • Ponte Vedra, Florida • Augusta, Kansas + 12 more
Conditions
Influenza
Interventions
Amantadine, Ribavirin, Oseltamivir, Oseltamivir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
69
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 58 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

NCT05091307
Conditions
COVID-19 Prevention
Interventions
Ad26.COV2.S, Placebo, Influenza Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
17
States / cities
Tempe, Arizona • San Diego, California • Coral Gables, Florida + 12 more
Conditions
Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
Interventions
Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
585 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more
Conditions
Influenza, Pandemic Influenza
Interventions
H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
6
States / cities
Wichita, Kansas • Lexington, Kentucky • Kansas City, Missouri + 3 more
Completed No phase listed Observational Results available

Evaluation of Moderate to Severe Influenza Outcomes in Children

NCT02979626
Conditions
Influenza, Otitis Media, Lower Resp Tract Infection, Encephalitic Infection, Myositis Viral, Fever
Interventions
Respiratory nasal swab
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Months to 8 Years
Enrollment
1,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Aurora, Colorado • Broomfield, Colorado
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of an Oral Vaccine to Prevent Avian Influenza

NCT01335347
Conditions
Avian Influenza, Bird Flu
Interventions
ND1.1, Placebo control
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study

NCT01522248
Conditions
Influenza Virus Vaccine
Interventions
Trivalent Inactivated Influenza vaccine
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Recruiting Phase 2 Interventional Accepts healthy volunteers

Systems Investigation of Vaccine Responses in Aging and Frailty

NCT05291676
Conditions
Influenza
Interventions
Fluzone, Fluad
Biological
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Influenza, Human
Interventions
Treatment Group Live Attenuated Flu Vaccine (LAIV)
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Completed No phase listed Observational Accepts healthy volunteers

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies

NCT04531787
Conditions
Influenza
Interventions
Influenza vaccine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative, Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation, Fluzone High-Dose vaccine, 2015-2016 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Recruiting No phase listed Observational Accepts healthy volunteers

Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2

NCT06848309
Conditions
Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host
Interventions
Bronchoscopy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
PHA1A
Interventions
Single Ascending Dose of SAB-176, Single Ascending Dose of Placebo
Drug
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Men's Engagement in Preventive Healthcare Through an Enhanced Cocoon Vaccination Strategy

NCT06437834
Conditions
Vaccines, Preventive Medicine
Interventions
Information Sheet, High-touch connect
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

NCT01612000
Conditions
Influenza
Interventions
PanBlok, rHA adjuvant
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Omaha, Nebraska • Rochester, New York • Austin, Texas + 2 more
Conditions
Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder, Aplastic Anemia, Myelodysplastic Syndromes, Chronic Leukemia, Lymphoma, Multiple Myeloma, Solid Tumor
Interventions
Total Body Irradiation 1200 cGy, Total Body Irradiation 200 cGy, Cyclophosphamide, Mesna, Cord Blood Infusion, Busulfan, Fludarabine, Melphalan
Radiation · Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
2 Months to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Rochester, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects

NCT04160975
Conditions
Flu, Human, Influenza, Human, Covid19
Interventions
Video about safety and effectiveness of adult seasonal flu vaccination
Behavioral
Lead sponsor
Harvard University
Other
Eligibility
18 Years to 51 Years · Male only
Enrollment
3,245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cambridge, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

NCT00743275
Conditions
Influenza
Interventions
Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Norfolk, Virginia
Completed Not applicable Interventional Accepts healthy volunteers

T-cell Response-Flu Risk in Older Adults

NCT00138398
Conditions
Influenza
Interventions
Commercial TriValent Split Influenza Virus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
20 Years to 99 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Farmington, Connecticut
Conditions
Influenza
Interventions
Influenza VLP Vaccine, TIV
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
6
States / cities
Pembroke Pines, Florida • Rochester, Minnesota • Providence, Rhode Island + 3 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

NCT00835926
Conditions
Influenza
Interventions
Influenza virus vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Influenza, Human, Human Immunodeficiency Virus I Infection
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 99 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia